With a focus on rare and challenging diseases, a marketing agency often supports development of new therapies that face a significant uphill battle in building awareness and highlighting unmet needs among patients and clinicians. Achieving these goals is a top priority for marketing and access teams in advance of an approval and launch, building the market by reinforcing the mechanism of action of a new therapy and the benefits it can deliver. Of the 10,000 estimated rare diseases, most have not even advanced to this very preliminary stage of marketing support because there is little or no research underway and no therapies positioned to advance to the finish line for years or decades. For some indications, however, the news is much better.
Without overstating the progress or minimizing the need for continued research, there are now many challenging rare diseases where advances in research has brought new hope to entire patient communities. Duchenne muscular dystrophy (DMD) is one of the most common and severe inherited neuromuscular disorders, affecting approximately 1 in every 3500-5000 male births worldwide. Caused by genetic mutations that significantly reduce or prevent the production of dystrophin, a protein essential for muscle stability and function, DMD leads to progressive muscle degeneration, loss of ambulation, respiratory decline, cardiomyopathy, and premature mortality. For decades, treatment options were limited primarily to supportive care with families facing a future shaped by inevitable disease progression.
The past 10 years, however, have represented a transformational period in the landscape of DMD research and care. Advances in many areas, including molecular genetics, gene-targeted therapies, disease-modifying treatments, cardiac and respiratory management, and multidisciplinary care have fundamentally altered expectations for patients and families. In December 2025, the U.S. Department of Health and Human Services recommended that states include DMD in their newborn screening protocols. While a cure remains elusive, the field has moved from simply managing symptoms toward modifying the disease itself by addressing the underlying genetic causes. At every stage in this remarkable progress, marketing communications has played an essential role in building awareness and helping clinicians, patients, and caregivers prepare for new therapies and make informed treatment decisions.
The progress in research has been so profound that it has also reshaped the priorities of the DMD community. As patients are living longer and maintaining function for extended periods, attention has increasingly shifted toward issues that were not previously priorities, including long-term quality of life, independence, transition to adulthood, mental health, education, employment, and comprehensive support services. Once again, marketing teams have continually evolved strategies to bring stakeholders the wider range of information they need to optimize the value and impact of advances in care.
The Emergence of Precision Medicine in DMD
Perhaps the most significant development in DMD research has been the rise of precision medicine. Rather than treating all patients identically, researchers have increasingly focused on therapies designed to target specific genetic mutations. DMD is caused by different mutations in one of the largest genes in the human genome. Because different mutations affect the gene in different ways, scientists recognized that therapies could potentially restore dystrophin production by correcting or bypassing specific genetic defects. This understanding led to the development of “exon-skipping” therapies that use synthetic molecules called antisense oligonucleotides to allow cells to “skip” faulty sections of the genetic code during protein production. By doing so, these therapies can restore production of a shorter but functional dystrophin protein.
Over the past decade, several exon-skipping therapies have received regulatory approval, including treatments targeting exons 51, 53, and 45. Although these therapies benefit only subsets of patients with specific mutations, they represented a historic milestone: the first approved treatments designed to address the root cause of DMD. The introduction of mutation-specific therapies marked a paradigm shift, making genetic testing even more important and enabling clinicians to identify patients who might benefit from emerging targeted treatments. This move toward personalized medicine continues to influence the direction of DMD research today.
As this promising research has advanced, marketing teams have played a central role in helping all stakeholders learn about and assess the clinical significance. Marketing strategies had to help the DMD community transition from a focus on palliative care to the potential to target the mechanism of disease. Research centers and industry, together with their agency partners, had to find the precise balance of messaging that would position DMD as a now treatable disease without overpromising. It was also necessary to provide entirely new levels of often complex medical and clinical information.
Gene Therapy: The New Era of Hope
Another major breakthrough in DMD (and many other diseases) has been the rapid advancement of gene therapy. Since the dystrophin gene is too large to fit into conventional viral vectors, researchers worked aggressively to overcome challenges in drug delivery by developing shortened versions known as microdystrophin genes. Using adeno-associated virus (AAV) vectors, scientists have been able to deliver these micro-dystrophin constructs directly into muscle cells, allowing the production of a functional dystrophin-like protein. Early clinical trials demonstrated encouraging levels of micro-dystrophin expression and improvements in biomarkers associated with muscle health.
The approval of the first gene therapy for DMD represented another landmark achievement for the neuromuscular community, though once again marketing and communications strategies had to reflect some very important considerations. While research has demonstrated that meaningful restoration of dystrophin production is achievable, questions remain regarding long-term durability, patient selection, immune responses, and access. Marketing strategies had to provide the right balance of precision, optimism, and caution. But even the most balanced marketing campaigns could not diminish the fact that gene therapy has justifiably changed expectations for what treatment can accomplish in DMD, especially for younger patients. Historically, treatment focused on strategies to slow decline. Today, researchers are increasingly focused on preserving muscle tissue before extensive damage occurs and potentially altering the trajectory of the disease from its earliest stages. This, in turn, introduced opportunities for marketing to embrace the importance of earlier intervention, newborn screening, expanded natural history studies, and earlier genetic diagnosis.
Advances in Corticosteroid Therapy
Corticosteroids have been the cornerstone of DMD treatment for decades, but even this established treatment protocol has seen significant advances in recent years. As a result, marketing strategies related to older therapeutic approaches have had to be updated.
Traditional corticosteroids such as prednisone and deflazacort remain important because they help preserve muscle strength, delay loss of ambulation, and slow respiratory and cardiac decline. However, long-term use is associated with a risk of substantial side effects including weight gain, behavioral changes, bone fragility, growth suppression, and metabolic complications. In response, researchers have worked to optimize dosing regimens and develop safer alternatives. This has included the introduction of dissociative steroids designed to retain anti-inflammatory benefits while reducing harmful side effects. Clinical trials have shown promising results in preserving muscle function with potentially improved tolerability.
Improvements in corticosteroid therapy reflect a broader trend in DMD care and messaging where the essential goal is to maximize functional benefits while minimizing treatment burden. As patients live longer, managing treatment-related complications has become increasingly important. And in a very happy challenge to address, marketing strategies in DMD have, of necessity, now been reshaped to engage with patients for much longer periods.
Improved Understanding of Disease Mechanisms
With the advances in DMD research, the need to deliver often complex scientific and medical information to patients and clinicians has expanded exponentially. To support informed decisions, communications efforts must help build a broader understanding of the biological processes that drive disease progression and that newer treatments are designed to target.
One important recent learning is the fact that muscle degeneration in DMD involves more than the absence of dystrophin. Factors including chronic inflammation, fibrosis, impaired muscle regeneration, oxidative stress, mitochondrial dysfunction, and altered signaling pathways can all contribute to disease progression. This deeper understanding has led to investigations of new therapeutic strategies targeting these downstream mechanisms. Clinical trials have explored anti-inflammatory agents, antifibrotic therapies, myostatin inhibitors, utrophin modulators, and drugs aimed at improving muscle regeneration.
Although not all investigational therapies have achieved their desired outcomes, each study has contributed valuable knowledge about DMD biology that can inform future therapeutic development. Recent research has also increasingly embraced innovative combination approaches, recognizing that optimal treatment may eventually require addressing multiple disease pathways simultaneously. Again, while the information that is necessary to deliver to the DMD community has become more complex and nuanced, it also highlights the new levels of progress and hope that research is bringing to this community.
Advances in Respiratory Management
In symptom management in DMD, one area that has undergone important changes is respiratory management. Noninvasive ventilation technologies have become more sophisticated, comfortable, and accessible. Improved cough-assist devices, airway clearance techniques, sleep monitoring, and pulmonary surveillance have significantly reduced respiratory complications. Earlier identification of respiratory weakness can support targeted intervention before serious complications develop. Multidisciplinary respiratory management has contributed substantially to increased life expectancy among individuals with DMD. With this progress, marketing agency strategies have had to expand to provide updated information about respiratory management for patients who will now often survive into adulthood. This remarkable reality presents many new communications opportunities and challenges for health care systems, families, and advocacy and support organizations.
The New Focus on Cardiac Care
While respiratory failure has been the leading cause of death and patient management challenge in DMD, improvements in respiratory management in recent years are a key factor in extending survival. One byproduct of this development is that cardiomyopathy has emerged as a major determinant of long-term outcomes and another essential focus in DMD communications strategies.
As evidence supporting earlier cardiac intervention has grown, care has evolved from reactive treatment to preventive management. Patients, caregivers, and clinicians all, as a result, need more information about strategies including use of advanced imaging techniques such as cardiac magnetic resonance imaging (MRI) that allow earlier detection of myocardial damage before symptoms appear. Guidance must also highlight the use of medications including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists that are increasingly used proactively rather than following overt cardiac dysfunction.
The growing emphasis on cardiology also highlights how the focus of DMD management has expanded beyond skeletal muscle to encompass whole-person health and long-term survival. Once again, marketing strategies are expanding into entirely new topic areas to keep pace.
Opportunities in Clinical Research
It is not surprising to note that most of the advances in DMD research have been directly supported by clinical trials. The DMD research ecosystem has matured considerably over the last decade. International patient registries, natural history databases, standardized outcome measures, and collaborative research networks have accelerated therapeutic development. Organizations such as Parent Project Muscular Dystrophy, Muscular Dystrophy UK, the World Duchenne Organization, and numerous other advocacy groups have played essential roles in connecting researchers, industry partners, regulators, and families. Individuals living with DMD and their families increasingly contribute to study design, endpoint selection, and regulatory discussions. This collaborative model has helped ensure that research priorities reflect outcomes that matter most to patients, including mobility, independence, fatigue, quality of life, and participation in everyday activities.
Marketing strategies and communications designed to support clinical research programs have been a fundamental focus in health care marketing for decades. The explosive growth in clinical research in many disease states, clearly reflected in DMD, has resulted in much higher demand for communication and marketing support to drive clinician participation and patient awareness and recruitment. These efforts must now often help stakeholders learn about, understand, and feel confident about many groundbreaking but untried advances in targeting DMD.
Marketing Strategies That Reflect New Patient Realities
As treatments have improved, expectations for patient health and lifespan in DMD have changed dramatically and are likely to continue to improve in the years ahead. A generation ago, many patients did not survive beyond their 20s. Today, it is not uncommon for patients to live into their 30s and beyond. This has transformed the conversation from one focused on inevitable disease progression and decline to one that embraces a range of life and lifestyle considerations including long-term therapy, adulthood, higher education, employment, relationships, and independent living.
Health care providers together with industry are increasingly developing structured programs to support a transition from pediatric to adult services. Neuromuscular clinics are expanding to meet the needs of a growing population of adults with DMD. This shift reflects one of the most profound impacts of recent scientific progress: DMD is increasingly being managed as a lifelong condition rather than exclusively as a pediatric disease. Marketing strategies are expanding based on this reality with information now often targeted toward adult patients who can make their own treatment decisions versus parents who are caregivers and decision-makers for their children.
Remaining Challenges and Looking Ahead
Despite remarkable progress, significant challenges remain in the management of DMD. Many therapies are mutation specific and benefit only subsets of patients. Gene therapies continue to raise questions about durability, repeat dosing, and long-term safety. Access to advanced treatments remains uneven across countries and health care systems, creating disparities in care. The cost of novel therapies can limit access for many eligible patients. Current therapies generally slow progression rather than restore muscle function. We are not yet anywhere near a “one and done” treatment protocol for DMD. Continued research is needed to develop more effective and broadly applicable options.
For health care marketing agencies such as CG Life that have extensive experience in DMD, teams must be continually ready to review and assess the impact of advances in research and refine marketing strategies to embrace them accurately and effectively. The next decade has the clear potential to deliver new levels of momentum in innovation. In just a few examples, researchers are exploring next-generation gene therapies, gene editing technologies such as CRISPR, improved exon-skipping approaches, stem cell-based therapies, and new combination treatment strategies. Advances in biomarkers and imaging may allow more precise monitoring of disease progression and treatment response. Artificial intelligence and data-driven research approaches may further accelerate drug development. With this great progress and potential, marketing strategies in DMD must, of necessity, continue to reflect the pace of change and complexity in research and the many new options that will be available to patients.
